Charles River Laboratorie... (CRL)
167.34
0.06 (0.04%)
At close: Mar 24, 2025, 3:59 PM
164.99
-1.40%
After-hours: Mar 24, 2025, 08:00 PM EDT
0.04% (1D)
Bid | 154.21 |
Market Cap | 8.56B |
Revenue (ttm) | 4.05B |
Net Income (ttm) | 12.25M |
EPS (ttm) | 0.2 |
PE Ratio (ttm) | 836.7 |
Forward PE | 16.58 |
Analyst | Hold |
Ask | 175.77 |
Volume | 326,939 |
Avg. Volume (20D) | 1,214,569 |
Open | 166.92 |
Previous Close | 167.28 |
Day's Range | 165.83 - 169.26 |
52-Week Range | 150.79 - 273.57 |
Beta | 1.45 |
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent r...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jun 23, 2000
Employees 18,700
Stock Exchange NYSE
Ticker Symbol CRL
Website https://www.criver.com
Analyst Forecast
According to 14 analyst ratings, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $179.5, which is an increase of 7.27% from the latest price.
Stock ForecastsNext Earnings Release
Charles River Laboratories International Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-6.34%
Charles River Laboratories shares are trading lowe...
Unlock content with
Pro Subscription
4 months ago
+13.53%
Charles River Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 outlook.